Patients with hereditary angioedema experienced fewer hospitalizations and ED and outpatient visits after beginning prophylactic treatment with berotralstat, according to a study presented at a recent conference. The study included 260 patients and showed a significant decrease in healthcare resource utilization, particularly for angioedema-related visits, after using berotralstat. These findings suggest that berotralstat is a cost-effective prophylactic therapy for managing HAE. While the data may have limitations, the researchers are continuing to study the benefits of berotralstat in real-world settings to further understand its positive impact on patients’ lives and the healthcare system.
Source link
Patients with hereditary angioedema visit the hospital less often with berotralstat
